MX356373B - Composiciones que comprenden un agente antibacterial y tazobactam. - Google Patents

Composiciones que comprenden un agente antibacterial y tazobactam.

Info

Publication number
MX356373B
MX356373B MX2013013079A MX2013013079A MX356373B MX 356373 B MX356373 B MX 356373B MX 2013013079 A MX2013013079 A MX 2013013079A MX 2013013079 A MX2013013079 A MX 2013013079A MX 356373 B MX356373 B MX 356373B
Authority
MX
Mexico
Prior art keywords
tazobactam
antibacterial agent
compositions
gram
composition
Prior art date
Application number
MX2013013079A
Other languages
English (en)
Other versions
MX2013013079A (es
Inventor
Subhash Bhagwat Sachin
Alam Jafri Mohammad
Vithalbhai Patel Manesh
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2013013079A publication Critical patent/MX2013013079A/es
Publication of MX356373B publication Critical patent/MX356373B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica que comprende un agente antibacteriano y tazobactam; donde la proporción de tazobactam con respecto al agente antibacteriano en la composición está en la escala de alrededor de 0.5 a alrededor de 2 g de tazobactam por gramo del agente antibacteriano.
MX2013013079A 2011-05-28 2011-08-01 Composiciones que comprenden un agente antibacterial y tazobactam. MX356373B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1587MU2011 2011-05-28
PCT/IB2011/053398 WO2012164358A1 (en) 2011-05-28 2011-08-01 Compositions comprising antibacterial agent and tazobactam

Publications (2)

Publication Number Publication Date
MX2013013079A MX2013013079A (es) 2013-12-06
MX356373B true MX356373B (es) 2018-05-25

Family

ID=44681394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013079A MX356373B (es) 2011-05-28 2011-08-01 Composiciones que comprenden un agente antibacterial y tazobactam.

Country Status (18)

Country Link
US (1) US10525043B2 (es)
EP (2) EP3412289A1 (es)
JP (1) JP5767745B2 (es)
KR (3) KR20170032480A (es)
CN (2) CN103608013A (es)
AU (1) AU2011369802B2 (es)
BR (1) BR112013030282B1 (es)
CA (1) CA2835907C (es)
DK (1) DK2714034T3 (es)
ES (1) ES2690725T3 (es)
HU (1) HUE040049T2 (es)
MX (1) MX356373B (es)
NZ (1) NZ616692A (es)
PL (1) PL2714034T3 (es)
PT (1) PT2714034T (es)
RU (1) RU2593363C2 (es)
WO (1) WO2012164358A1 (es)
ZA (1) ZA201307837B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016022439A2 (pt) * 2014-03-29 2017-08-15 Wockhardt Ltd Composições farmacêuticas que compreendem cefepima ou sulbactama
AU2017242134B2 (en) * 2016-03-31 2022-12-01 Wockhardt Limited Antibacterial compositions
CA2983256A1 (en) * 2016-03-31 2017-10-05 Wockhardt Limited Antibacterial compositions
MY186775A (en) * 2016-03-31 2021-08-19 Wockhardt Ltd Antibacterial compositions and methods
EP3693374B1 (en) 2017-10-05 2022-01-26 FUJIFILM Corporation Novel 2-carboxypenam compound or salt thereof, pharmaceutical composition containing said compound or salt, and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565456A (zh) * 2003-06-14 2005-01-19 张哲峰 一种头孢吡肟抗菌组合药物
CN1565455A (zh) * 2003-07-04 2005-01-19 成都博瑞医药科技开发有限公司 治疗产超广谱β－内酰胺酶细菌感染用的抗菌素组合物
CN101060846A (zh) * 2004-12-02 2007-10-24 维纳斯药业有限公司 采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
WO2007086014A1 (en) 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefpirome, tazobactam and linezolid
EP1958630A1 (en) * 2007-02-13 2008-08-20 LEK Pharmaceuticals d.d. Antibacterial combination of a tricyclic carbapenem and an antibiotic
KR101787113B1 (ko) * 2008-08-28 2017-11-15 화이자 안티-인펙티브스 에이비 세프타롤린을 포함하는 조성물 및 치료 방법

Also Published As

Publication number Publication date
RU2013157933A (ru) 2015-07-10
BR112013030282A2 (pt) 2017-11-07
RU2593363C2 (ru) 2016-08-10
KR20140035376A (ko) 2014-03-21
CA2835907C (en) 2017-03-21
EP3412289A1 (en) 2018-12-12
DK2714034T3 (en) 2018-10-08
PL2714034T3 (pl) 2018-12-31
EP2714034B1 (en) 2018-07-25
EP2714034A1 (en) 2014-04-09
KR20180016645A (ko) 2018-02-14
JP5767745B2 (ja) 2015-08-19
CN103608013A (zh) 2014-02-26
KR20170032480A (ko) 2017-03-22
BR112013030282B1 (pt) 2020-09-29
MX2013013079A (es) 2013-12-06
AU2011369802B2 (en) 2016-09-08
PT2714034T (pt) 2018-10-30
KR101850265B1 (ko) 2018-04-18
WO2012164358A1 (en) 2012-12-06
US10525043B2 (en) 2020-01-07
AU2011369802A1 (en) 2013-10-31
ZA201307837B (en) 2015-01-28
HUE040049T2 (hu) 2019-02-28
CN109481439A (zh) 2019-03-19
CA2835907A1 (en) 2012-12-06
US20140162995A1 (en) 2014-06-12
ES2690725T3 (es) 2018-11-22
NZ616692A (en) 2015-07-31
JP2014514305A (ja) 2014-06-19

Similar Documents

Publication Publication Date Title
JOP20180102A1 (ar) مركب صيدلاني
PH12012502159A1 (en) Pharmaceutical compositions and methods of making same
WO2011131943A3 (en) Pharmaceutical compositions
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
MX2013001677A (es) Formulaciones estables de linaclotida.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX356373B (es) Composiciones que comprenden un agente antibacterial y tazobactam.
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
WO2012093973A3 (en) Compositions in the form of tablets comprising acarbose
IN2014DN03010A (es)
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
WO2015071299A3 (en) Stable pharmaceutical glycylcycline compositions
WO2012007758A3 (en) Pharmaceutical formulations
PH12015501428A1 (en) Antibacterial compounds
WO2014006601A3 (en) Nanoparticle compositions of antibacterial compounds and other uses thereof

Legal Events

Date Code Title Description
FG Grant or registration